Online inquiry

IVTScrip™ mRNA-Anti-IL33, ANB020(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2974MR)

This product GTTS-WQ2974MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets IL33 gene. The antibody can be applied in Esophagitis eosinophilic research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001199640.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 90865
UniProt ID O95760
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL33, ANB020(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ2974MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5918MR IVTScrip™ mRNA-Anti-CD274, CK-301(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CK-301
GTTS-WQ12413MR IVTScrip™ mRNA-Anti-CD3E, NI-0401(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA NI-0401
GTTS-WQ6577MR IVTScrip™ mRNA-Anti-EGFR, DC-1630423(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA DC-1630423
GTTS-WQ11911MR IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MLN-1202
GTTS-WQ1480MR IVTScrip™ mRNA-Anti-CD79B, ACD79B-VCMMAE(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ACD79B-VCMMAE
GTTS-WQ8159MR IVTScrip™ mRNA-Anti-TNFRSF1A, HL036337(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HL036337
GTTS-WQ10977MR IVTScrip™ mRNA-Anti-IL17A&IL17F, MCAF-5352A(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MCAF-5352A
GTTS-WQ6267MR IVTScrip™ mRNA-Anti-HA, CR-6261(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CR-6261
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW